BCL2L1 and cancer: Analysis of BCL2L1, a key anti-apoptotic gene, showed elevated transcript levels were linked with significantly worse survival (p = 0.04), suggesting that tumors with heightened anti-apoptotic capacity may rapidly evade cancer therapies (Figure 5B).